News stories about Collegium Pharmaceutical (NASDAQ:COLL) have trended somewhat positive on Tuesday, Accern reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Collegium Pharmaceutical earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 45.6282185048454 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the media headlines that may have impacted Accern’s scoring:

Shares of Collegium Pharmaceutical (COLL) traded up 0.66% during midday trading on Tuesday, hitting $10.65. The company had a trading volume of 320,430 shares. Collegium Pharmaceutical has a 1-year low of $8.90 and a 1-year high of $20.55. The firm’s market capitalization is $314.88 million. The stock has a 50 day moving average price of $10.58 and a 200 day moving average price of $13.54.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.09. The business had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $4.07 million. Collegium Pharmaceutical had a negative net margin of 1,319.39% and a negative return on equity of 93.73%. On average, equities analysts anticipate that Collegium Pharmaceutical will post ($3.00) EPS for the current fiscal year.

Several equities analysts have weighed in on the company. Janney Montgomery Scott reissued a “buy” rating and set a $25.00 price objective on shares of Collegium Pharmaceutical in a report on Monday, June 12th. Zacks Investment Research downgraded Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. HC Wainwright initiated coverage on Collegium Pharmaceutical in a research report on Monday. They set a “buy” rating and a $21.00 target price on the stock. BidaskClub downgraded Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Finally, ValuEngine upgraded Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $21.29.

ILLEGAL ACTIVITY NOTICE: “Collegium Pharmaceutical (COLL) Earns Media Sentiment Rating of 0.13” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/12/collegium-pharmaceutical-coll-earns-media-sentiment-rating-of-0-13.html.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Insider Buying and Selling by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Stock Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.